Use of dietary phytochemicals for inhibition of trimethylamine N-oxide formation

• Published in: The Journal of nutritional biochemistry Vol. 91; p. 108600
• Main Authors: Iglesias-Carres, Lisard, Hughes, Michael D., Steele, Cortney N., Ponder, Monica A., Davy, Kevin P., Neilson, Andrew P.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-05-2021
• Subjects: Atherosclerosis; Cardiovasculardisease; Phytochemicals; TMAO; TMAO; FXR; NF-κβ; NO; eNOS; MCP-1; OTUs; HR; ICAM-1; AUC; OAT2; MACE; LDL-R; Atherosclerosis; DMB; ApoE; VLDL-c; OR; LDL-c; rRNA; SOD; TMA; FMO3; IL-1β; MAPK; IL-6; TC; CVD; HDL-c; Cardiovasculardisease; VCAM-1; Phytochemicals; TG; TNF-α; TXNIP; CVR
• ISSN: 0955-2863; 1873-4847
• DOI: 10.1016/j.jnutbio.2021.108600

Trimethylamine-N-oxide (TMAO) has been reported as a risk factor for atherosclerosis development, as well as for other cardiovascular disease (CVD) pathologies. The objective of this review is to provide a useful summary on the use of phytochemicals as TMAO-reducing agents. This review discusses the main mechanisms by which TMAO promotes CVD, including the modulation of lipid and bile acid metabolism, and the promotion of endothelial dysfunction and oxidative stress. Current knowledge on the available strategies to reduce TMAO formation are discussed, highlighting the effect and potential of phytochemicals. Overall, phytochemicals (i.e., phenolic compounds or glucosinolates) reduce TMAO formation by modulating gut microbiota composition and/or function, inhibiting host's capacity to metabolize TMA to TMAO, or a combination of both. Perspectives for design of future studies involving phytochemicals as TMAO-reducing agents are discussed. Overall, the information provided by this review outlines the current state of the art of the role of phytochemicals as TMAO reducing agents, providing valuable insight to further advance in this field of study.